Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-08	SEK 8.820	+0.68%	2,329
26-10-07	SEK 8.760	-2.01%	2,311
26-10-06	SEK 8.940	-0.89%	3,378
26-10-05	SEK 9.020	-1.53%	9,147
26-10-02	SEK 9.160	+2.69%	17,095

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Annexin Pharmaceuticals AB

Company calendar

Market Closed - Nasdaq Stockholm 12:00:00 2026-10-08 EDT			5-day change	1st Jan Change
8.820 ^SEK	+0.68%		-1.12%	-55.45%

09-25	12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
09-22	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW

Market Cap	76.89M 7.69M 6.87M 6.4M 5.82M 10.95M 745M 11.05M 30.08M 378M 28.87M 28.24M 1.22B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	76.89M 7.69M 6.87M 6.4M 5.82M 10.95M 745M 11.05M 30.08M 378M 28.87M 28.24M 1.22B	EV / Sales 2026 *	1.66x	EV / Sales 2027 *	2.32x
Free-Float	54.78%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ANNX	Delayed
Deutsche Boerse AG	Q910	Delayed

09-25	12 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
09-22	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
09-17	Annexin Pharmaceuticals Doses First Patient in Expanded Retinal Vein Occlusion Trial	MT
09-17	Annexin Pharmaceuticals AB Treats First Patient With Vanexin Following Anti-VEGF Injection In The NEXUS Study	CI
08-21	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT
08-21	Annexin Pharmaceuticals Advances the Nexus Study to Include Patients Who Received an Anti-Vegf Injection	CI
08-20	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV	CI
07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news: Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

09-17	First patient treated with vanexin following anti-VEGF injection in the NEXUS study	AQ
09-10	Annexin Pharmaceuticals to Present at Investing in Life Science on September 22	AQ
08-21	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection	AQ
08-20	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV	AQ
07-21	Annexin updates on nine patients treated in NEXUS study	AQ

1 day	+0.68%
1 week	-1.12%
1 month	-34.67%
3 months	-30.82%
6 months	-33.68%
Current year	-55.45%

1 week	8.66	9.2
1 month	8.54	13.45
Current year	8.54	23.6
1 year	8.54	29.8
3 years	8.54	97.6
5 years	8.54	169
10 years	8.54	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	2018-12-31
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	2015-12-31
Susanne Andersson DFI	Director of Finance/CFO	55	2023-04-10

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	2016-12-31
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	2023-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	+0.68%	-1.12%	-67.33%	-87.98%	7.62M
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	74.68B
ARGENX SE	-15.86%	-16.16%	+2.68%	+50.90%	58.7B
LONZA GROUP AG	-2.39%	+0.50%	+3.41%	+31.33%	48.36B
REVOLUTION MEDICINES, INC.	-6.35%	-8.63%	+293.39%	+651.28%	43.05B
IQVIA HOLDINGS INC.	+0.30%	-0.71%	+29.05%	+30.33%	42.48B
BEONE MEDICINES AG	-3.82%	-2.41%	-0.27%	+101.36%	41.39B
CELLTRION, INC.	-2.13%	-2.18%	+7.51%	+50.31%	31.29B
BIONTECH SE	-3.35%	-4.95%	-13.38%	-17.22%	23.93B
GENMAB A/S	-5.27%	+1.86%	+12.19%	-5.34%	22.24B
Average	-4.14%	-2.95%	+31.19%	+89.29%	38.61B
Weighted average by Cap.	-5.10%	-3.89%	+45.82%	+118.20%

	2026 *	2027 *
Net sales	46.3M 4.63M 4.13M 3.86M 3.5M 6.59M 448M 6.66M 18.11M 228M 17.38M 17M 733M	33.1M 3.31M 2.96M 2.76M 2.5M 4.71M 321M 4.76M 12.95M 163M 12.43M 12.16M 524M
Net income	-11.5M -1.15M -1.03M -958K -870K -1.64M -111M -1.65M -4.5M -56.59M -4.32M -4.22M -182M	-24.9M -2.49M -2.22M -2.07M -1.88M -3.55M -241M -3.58M -9.74M -123M -9.35M -9.14M -394M
Net Debt	-	-